• 1
    Hayes PC, Westaby D, Williams R. Effects and mechanisms of action of isosorbide-5-mononitrate. Gut 1988; 29: 757765.
  • 2
    Navasa M, Chesta J, Bosch J, Rodes J. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis: effects on splanchnic and systemic hemodynamics and liver function. Gastroenterology 1989; 96: 11101118.
  • 3
    Garcia-Pagan JC, Feu F, Navasa M, Bru C, Ruiz de Arbol L, Bosch J, Rodes J. Long-term hemodynamic effects of isosorbide-5-mononitrate in patients with cirrhosis and portal hypertension. J Hepatol 1990; 11: 189195.
  • 4
    Grose RD, Plevris JN, Redhead DN, Bouchier IAD, Hayes PC. The acute and chronic effects of isosorbide-5-mononitrate on portal hemodynamics in cirrhosis. J Hepatol 1994; 20: 542547.
  • 5
    Garcia-Pagan JC, Navasa M, Bosch J, Bru C, Pizcueta P, Rodes J. Enhancment of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis. Hepathology 1990; 11: 230238.
  • 6
    Garcia-Pagan JC, Feu F, Bosch J, Rodes J. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: a randomized controlled study. Ann Intern Med 1991; 114: 869873.
  • 7
    Angelico M, Carli L, Piat C, Gentile S, Rinaldi V, Bologna E, Capocaccia L. Isosorbide-5-Mn versus propranolol in the prevention of first bleeding in cirrhosis. Gastroenterology 1993; 104: 14601465.
  • 8
    Bertoni G, Sassatelli R, Fornaciari G, Briglia R, Tansini P, Grisendi A, Pedretti G. et al. Oral isosorbide-5-mononitrate reduces the rebleeding rate during the course of injection schlerotherapy for esophageal varices. Scand J Gastroenterol 1994; 29: 363370.
  • 9
    Salmeron JM, Ruiz de Arbol L, Gines A, Garcia-Pagan JC, Gines P, Feu F, Claria J. et al. Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis. Hepathology 1993; 17: 800806.
  • 10
    Vorobioff J, Picabea E, Gamen M, Villavicencio R, Bordato J, Bessone F, Tanno H. et al. Propranolol compared with propranolol plus isosorbide dinitrate in portal-hypertensive patients: long-term hemodynamic and renal effects. Hepathology 1993; 18: 477484.
  • 11
    Morillas RM, Planas R, Cabre E, Galan A, Quer JC, Feu F, Garcia Pagan JC. et al. Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effects. Hepathology 1994; 20: 15021508.
  • 12
    Merkel C, Gatta A, Donada C, Enzo E, Marini R, Amodio P, Torboli P. et al. Long-term effect of nadolol or nadolol plus isosorbide-5-mononitrate on renal function and ascites formation in patients with cirrhosis. Hepathology 1995; 22: 808813.
  • 13
    The North Italian Endoscopic Club. Prediction of the first variceal hemorrage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med 1988; 319: 983989.
  • 14
    Heyrovsky A. A new method for the determination of inulin in plasma and urine. Clin Chim Acta 1956; 1: 470474.
  • 15
    Brun C. A rapid method for determination of paraminohippuric acid in kidney function tests. J Lab Clin Med 1951; 37: 955958.
  • 16
    Salerno F, Badalamenti S, Incerti PL, Capozza L, Mainardi L. Renal response to atrial natriuretic peptide in patients with advanced liver cirrhosis. Hepathology 1988; 8: 2126.
  • 17
    Blei AT, Gottstein J. Isosorbide dinitrate in experimental portal hypertension: a study of factors that modulate the hemodynamic response. Hepathology 1986; 6: 107111.
  • 18
    Merkel C, Finucci G, Zuin R, Bazzerla G, Bolognesi M, Sacerdoti D, Gatta A. Effects of isosorbide dinitrate on portal hypertension in alcoholic cirrhosis. J Hepatol 1987; 4: 174180.
  • 19
    Elkayam U. Tolerance to organic nitrates: evidence, mechanisms, clinical relevance, and strategies for prevention. Ann Intern Med 1991; 114: 667677.